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Pathological glomerular hyposialylation has been im-
plicated in certain unexplained glomerulopathies, in-
cluding minimal change nephrosis, membranous glo-
merulonephritis, and IgA nephropathy. We studied
our previously established mouse model carrying a
homozygous mutation in the key enzyme of sialic
acid biosynthesis, N-acetylglucosamine 2-epimerase/
N-acetylmannosamine kinase. Mutant mice died be-
fore postnatal day 3 (P3) from severe glomerulopathy
with podocyte effacement and segmental glomerular
basement membrane splitting due to hyposialylation.
Administration of the sialic acid precursor N-acetyl-
mannosamine (ManNAc) led to improved sialylation
and survival of mutant pups beyond P3. We deter-
mined the onset of the glomerulopathy in the embry-
onic stage. A lectin panel, distinguishing normally
sialylated from hyposialylated glycans, used WGA,
SNA, PNA, Jacalin, HPA, and VVA, indicating glomer-
ular hyposialylation of predominantly O-linked gly-
coproteins in mutant mice. The glomerular glycopro-
teins nephrin and podocalyxin were hyposialylated
in this unique murine model. ManNAc treatment ap-peared to ameliorate the hyposialylation status of mu-
tant mice, indicated by a lectin histochemistry pattern
similar to that of wild-type mice, with improved sia-
lylation of both nephrin and podocalyxin, as well as
reduced albuminuria compared with untreated mu-
tant mice. These findings suggest application of our
lectin panel for categorizing human kidney speci-
mens based on glomerular sialylation status. More-
over, the partial restoration of glomerular architec-
ture in ManNAc-treated mice highlights ManNAc as a
potential treatment for humans affected with disor-
ders of glomerular hyposialylation. (Am J Pathol 2012,
180:1431–1440; DOI: 10.1016/j.ajpath.2011.12.023)
Sialic acids, the most abundant terminal carbohydrates
on glycoconjugates of eukaryotic cells, are involved in
cellular interactions, signaling, and immune responses,
among other processes.1–4 Additionally, sialic acids reg-
ulate the polyanionic component of the glomerular glyco-
calyx, which is integral to permeability selectivity.5,6 Hy-
posialylation was therefore proposed as a cause of
certain unexplained human glomerulopathies; renal biop-
sies from patients with minimal change nephrosis and
membranous glomerulonephritis show decreased sialic
acid staining of podocyte membranes.7,8 Biopsies of
membranous glomerulonephritis kidneys also exhibit re-
duced sialic acid staining of the lamina densa externa of
Supported by the Intramural Research Programs of the National Human
Genome Research Institute, the National Dental and Craniofacial Re-
search Institute, and the National Institute of Diabetes and Digestive and
Kidney Diseases, NIH, Bethesda, MD.
Accepted for publication December 9, 2011.
S.K. and T.Y. contributed equally to this work.
This work was performed in partial fulfillment of the requirements for
Ph.D. degree of T.Y., Sackler Faculty of Medicine, Tel Aviv University, Tel
Aviv, Israel.
Disclosures: M.H., I.M., E.D.K., and W.A.G. are co-inventors on patent
PCT/US2008/006895 “N-acetyl mannosamine as a therapeutic agent.”
Supplemental material for this article can be found on http://ajp.
amjpathol.org or at doi: 10.1016/j.ajpath.2011.12.023.
Address reprint requests to Marjan Huizing, Ph.D., Head, Cell Biology
of Metabolic Disorders Unit, Medical Genetics Branch, NHGRI, NIH,
Bethesda, MD 20892-1851. E-mail: mhuizing@mail.nih.gov.
1431
1432 Kakani et al
AJP April 2012, Vol. 180, No. 4the glomerular basement membrane (GBM),8 and serum
from patients with IgA nephropathy exhibits hyposialy-
lated circulating IgA1, resulting in the loss of nephrin, a
podocyte structural protein.9,10
One of the best characterized glomerular sialogly-
coproteins is podocalyxin, a CD-34-related sialomucin
highly expressed in podocyte membranes, which con-
tributes to proper foot process and slit diaphragm forma-
tion.11–13 Podocalyxin interacts with the actin cytoskele-
ton via ezrin and the Na/H-exchanger regulatory factor
2 (NHERF-2).14,15 This interaction is disrupted in various
experimental models of nephrotic syndrome. In mice and
rats, removal of sialic acids by sialidase treatment results
in foot process effacement.5,15 In rats, reduced sialylation
of podocalyxin and consequent loss of normal foot pro-
cess architecture occurs after injection with the neutral-
izing agents puromycin aminonucleoside (PAN) or prota-
mine sulfate.16–20
N-Acetylneuraminic acid (Neu5Ac) is the most abundant
mammalian sialic acid and is the precursor of all other sialic
acids; it is often referred to simply as sialic acid.1,3,4 Intra-
cellular Neu5Ac synthesis is initiated by the bifunctional
rate-limiting enzyme uridine diphospho-N-acetylgluco-
samine (UDP-GlcNAc) 2-epimerase/N-acetylmanno-
samine (ManNAc) kinase (GNE/MNK), encoded by the
GNE gene.21,22 Tight regulation of sialic acid synthesis is
provided by feedback inhibition of UDP-GlcNAc 2-epi-
merase activity by the downstream product cytidine
monophosphate-Neu5Ac (CMP-sialic acid).21,23 Human
GNE mutations result in hereditary inclusion body myop-
athy (HIBM; OMIM 600737), an autosomal recessive neu-
romuscular disorder of adult onset, characterized by
slowly progressive muscle weakness and atrophy.22,24,25
More than 500 HIBM patients exist worldwide, harboring
60 different GNE mutations. HIBM patients have reces-
sive (and predominantly missense) mutations in either
enzymatic domain of GNE, leading to decreased enzyme
activity and, presumably, to decreased sialic acid pro-
duction.22,26,27 Whether hyposialylation is the main
cause of the neuromuscular symptoms in HIBM pa-
tients remains uncertain.
We previously generated an HIBM mouse model to
study the disease pathology and to test potential sialic
acid replacement therapies for HIBM. Because the Gne
knockout mouse is embryonic lethal,28 we created a
gene-targeted knockin mouse model, mimicking the GNE
M712T Persian Jewish HIBM founder mutation.29 Unex-
pectedly,90% of homozygous mutant (GneM712T/M712T)
mice did not survive beyond postnatal day 3 (P3). At P2,
mutant pups displayed severe hematuria, proteinuria,
and a glomerulopathy with effacement of the podocyte
foot processes and segmental splitting of the GBM, likely
due to hyposialylation of specific membrane glycopro-
teins, including podocalyxin.29 For a possible therapy,
we explored dietary supplementation with the uncharged
sialic acid precursor N-acetylmannosamine (ManNAc),
the intermediate product of the GNE/MNK enzyme. In the
absence of MNK activity, ManNAc can be converted to
ManNAc-6P by N-acetylglucosamine (GlcNAc) kinase,
thus bypassing the kinase domain mutation in our
knockin mice.30 ManNAc supplementation increasedsurvival of GneM712T/M712T pups beyond P3 to approxi-
mately 50%; survivors showed improved glomerular his-
tology and podocyte ultrastructure, as well as increased
podocalyxin sialylation.29
The renal phenotype in our GneM712T/M712T knockin
model differed from that of HIBM patients, who have
normal urinary laboratory findings and no indications of
renal abnormalities.31 This discrepancy may be attrib-
uted to differences between species in the relative im-
portance of sialic acid to the kidney, and to the type of
sialic acid present. Most mammalian species, including
mice, use N-glycolylneuraminic acid (Neu5Gc) as their
main sialic acid. Humans, however, rely mainly on
Neu5Ac, because humans have evolutionarily lost the
ability to synthesize Neu5Gc.32 Protein glycosylation pat-
terns may also differ. For example, the glomerular sialo-
protein podocalyxin varies between species in its contin-
gent of N- and O-linked glycosylation sites.33 Further
research might elucidate these species-specific glycosy-
lation issues. Although ourGneM712T/M712T knockin model
did not live long enough to recapitulate the features of the
human adult-onset myopathy, the mice illustrated the im-
portance of sialic acid in kidney development and func-
tion. To our knowledge, this GneM712T/M712T mouse is the
first genetic model of podocyte injury and GBM splitting
due to hyposialylation.
In the present study, we extensively characterized the
glomerulopathy of the GneM712T/M712T mouse. With ultra-
structural, lectin, and antibody analysis of kidney speci-
mens, we established the onset of hyposialylation in the
embryonic stage. We designed a lectin staining panel that
convincingly determined glomerular hyposialylation of mu-
tant mice. The glomerular glycoprotein nephrin was recog-
nized as a novel marker for glomerular hyposialylation, in
addition to the previously recognized podocalyxin. We
demonstrate that ManNAc treatment of mutant mice par-
tially rescued their severe albuminuria, their glomerular hy-
posialylation in general, and specifically their nephrin and
podocalyxin hyposialylation. These findings indicate that
hyposialylation may underlie unexplained human glomeru-
lopathies; identification of such disorders may aid develop-
ment of therapies for this relatively unexplored class of renal
disorders. Our lectin staining panel can be used to diag-
nose human renal disorders of hyposialylation, for which
ManNAc might be explored as a therapeutic option.
Materials and Methods
Mouse Studies
GneM712T/M712T knockin mice were generated as de-
scribed previously.29 Animals were housed in a specific
pathogen-free facility, accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International, in accordance with the Guide for the Care
and Use of Laboratory Animals (NIH publication no. 85–
23). All mouse procedures were performed in accor-
dance with protocol G04-3, approved by the Institutional
Animal Care and Use Committee of the National Human
Genome Research Institute.
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supplemented with 5 mg/mL ManNAc (1.0 g/kg per
day) (New Zealand Pharmaceuticals, Palmerston North,
New Zealand). Nursing females continued to receive
ManNAc until the pups were euthanized or weaned. Un-
treated mice were euthanized at P2, and ManNAc-treated
mice were euthanized at P5 to P10. Heterozygotic speci-
mens developed no clinical phenotype, normal podocyte
foot processes were observed under electron microscopy,
and no hyposialylation of podocalyxin was observed with
Western blotting. We therefore present the results only of
wild-type and homozygous mutant specimens.29
Mouse Kidney Histology
Mouse kidneys were fixed in 4% paraformaldehyde for 48
hours, dehydrated in 70% ethanol, and paraffin-embed-
ded for sectioning. Tissue sections (5 m) were stained
with H&E or with Masson’s trichrome according to standard
procedures (American Histolabs, Gaithersburg, MD) or
were subjected to histochemistry or immunohistochemistry
with a variety of antibodies and lectins. Juxtamedullary
glomeruli were analyzed in H&E-stained slides of two em-
bryos per genotype (two sections per embryo), and at least
10 untreated animals at P2 per genotype (one section per
animal) and 10 ManNAc-treated animals at P5 per geno-
type (one section per animal). Representative glomeruli
were digitally imaged with a Zeiss Axiovert 200M micro-
scope (Zeiss, Thornwood, NY).
Electron Microscopy
For transmission electron microscopy, mouse kidney
samples were fixed overnight at 4°C in 2% glutaralde-
hyde in 0.1 mol/L cacodylate buffer (pH 7.4) and washed
with cacodylate buffer. The tissues were then fixed with
2% OsO4 for 2 hours, washed again with 0.1 mol/L ca-
codylate buffer, washed with water, and placed in 1%
uranyl acetate. The tissues were then serially dehydrated
in ethanol and propylene oxide and embedded in EMbed
812 resin (Electron Microscopy Sciences, Hatfield, PA).
Thin sections (80 nm) were obtained using a Leica
Ultracut-UCT ultramicrotome (Leica Microsystems, Deer-
field, IL), placed onto 300-mesh copper grids, and
stained with saturated uranyl acetate in 50% methanol
followed by lead citrate. The grids were viewed under a
JEM-1200EXII electron microscope (JEOL, Tokyo, Ja-
pan) at 80 kV; images were recorded on a XR611M,
mid-mounted, 10.5 megapixel CCD camera (Advanced
Microscopy Techniques, Danvers, MA). Two embryos
per genotype at embryonic day E19 were analyzed (three
sections each), and six mutant pups and four wild-type
heterozygous pups at P2 (three sections each) and eight
ManNAc-treated pups per genotype (three sections
each) at different ages beyond P3 (P5, P10, and P19).
Urine Gel Electrophoresis
Mouse urine samples (2 L, from a one-time urine col-
lection from five mice per genotype before and after
ManNAc treatment) were electrophoresed in Laemmlisample buffer supplemented with -mercaptoethanol
(Bio-Rad Laboratories, Hercules, CA) on 4% to 20% Tris-
glycine polyacrylamide gradient gels (Novex; Invitrogen,
Carlsbad, CA). Pure bovine serum albumin (Amersham;
GE Healthcare, Piscataway NJ) was loaded for quantifi-
cation purposes. Gels were stained with Coomassie Bril-
liant Blue R-250 (Bio-Rad Laboratories) for 20 minutes
and washed with R-250 destaining solution (Bio-Rad Lab-
oratories), according to the manufacturer’s protocols.
Semiquantitative densitometry was performed on the
Coomassie-stained albumin signals.
Lectin Histochemistry
For lectin histochemistry, fluorescein isothiocyanate
(FITC) labeled lectins WGA, PNA, Jacalin, HPA, and VVA
were purchased from EY Laboratories (San Mateo, CA)
and SNA was purchased from Vector Laboratories (Bur-
lingame, CA). Paraffin-embedded sections were depar-
affinized [two times for 45 minutes each in Hemo-De
solvent (Scientific Safety Solvents, Keller, TX)] and rehy-
drated (two times for 5 minutes each in 100%, 70%, and
50% ethanol), followed by antigen retrieval (microwaved
three times for 5 minutes each in 0.01 mol/L sodium
citrate, pH 6.4, at 100%, 50%, and 30% power; Panaso-
nic Genius 1300W microwave), and blocking in carbohy-
drate-free blocking solution (Vector Laboratories). The
slides were incubated at 4°C overnight with each lectin
aliquoted in carbohydrate-free blocking solution (FITC-
HPA, 5 g/mL; FITC-SNA, 5 g/mL; FITC-VVA, 5 g/mL;
FITC-WGA, 15 g/mL; FITC-PNA, 30 g/mL; FITC-Jaca-
lin, 50 g/mL). Washes were performed with 0.1% Triton-
X-100 in 1 Tris-buffered saline. The lectin-stained slides
were incubated in 0.3% Sudan Black in 70% ethanol
solution to reduce autofluorescence. In addition, to verify
lectin specificity, each lectin was incubated with its spe-
cific inhibitory carbohydrate for 1 hour before overnight
incubation on a slide. The inhibitory carbohydrates used
were Neu5Ac (Toronto Research Chemicals, North York,
ON, Canada) for WGA and SNA, lactose (C-6010-10; EY
Laboratories) for PNA, galactose (C-6003-10; EY Labo-
ratories) for Jacalin, and GalNAc (C-6000-10; EY Labo-
ratories) for HPA and VVA. Results of these control ex-
periments, indicating the specificity of each lectin used in
this panel, are presented in Supplemental Figure S1
(available at http://ajp.amjpathol.org). All slides were
mounted in Vectashield including the nuclear stain DAPI
(H-1200; Vector Laboratories).
Fluorescence imaging of multiple juxtamedullary glom-
eruli per slide was performed under a Zeiss 510 META
confocal laser-scanning microscope. All fluorescent im-
ages represent collapsed stacks of confocal Z-sections,
imaged with a 63 objective. For each lectin, two em-
bryos per genotype at E19 were analyzed (two sections
per lectin per genotype), and at least 10 mutant pups and
10 wild-type/heterozygous pups at P2 (three sections per
lectin per genotype), as well as more than 10 ManNAc-
treated pups per genotype (three sections per lectin per
genotype) at different ages beyond P3 (mainly at P5).
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Frozen kidney specimens were homogenized in CelLytic
MT buffer (Sigma-Aldrich, St. Louis, MO) with protease
inhibitors (Complete Mini Protease Inhibitor Cocktail;
Roche Applied Science, Indianapolis, IN). For the neur-
aminidase enzymatic treatments, protein homogenates
were incubated for 2 hours at 37°C with approximately 1
mU/g of neuraminidase (P0720S; New England Biolabs,
Ipswich, MA). Equal amounts of protein (10 to 30 g)
were electrophoresed in Laemmli sample buffer supple-
mented with -mercaptoethanol (Bio-Rad Laboratories)
on 4% to 20% Tris-glycine gels (Novex; Invitrogen) and
electroblotted onto 0.45-m Hybond ECL nitrocellulose
membranes (GE Healthcare). Membranes were blocked
(10% fat-free milk) and incubated with goat-anti-mouse
podocalyxin (AF1556; R&D Systems, Minneapolis, MN)
or guinea pig-anti-mouse nephrin (GP-N2; PROGEN Bio-
technik, Heidelberg, Germany) antibodies, and mouse
monoclonal -tubulin antibodies (loading control; Sigma-
Aldrich), followed by horseradish peroxidase-conjugated
secondary antibodies [GE Healthcare and Santa Cruz
Biotechnology (Santa Cruz, CA)]. Results were visualized
with enhanced chemiluminescence (ECL Western blot-
ting detection reagents; GE Healthcare) and exposure to
CL-XPosure film (Pierce; Thermo Fisher Scientific, Rock-
ford, IL).
Neuraminidase Expression by Quantitative Real-
Time PCR
RNA was extracted frommouse kidneys using an RNeasy
mini kit (Qiagen, Valencia, CA). TaqMan primers and
probes were ordered as premanufactured assays on
demand: mouse lysosomal neuraminidase 1 (Neu1;Mm00456846) and mouse cytosolic neuraminidase 2
(Neu2; Mm00479238) (Applied Biosystems, Foster City,
CA). The housekeeping gene B2M (2 microglobulin,
Mm00437762; Applied Biosystems) was used as internal
control gene. All quantitative real-time PCR reactions and
subsequent analyses were performed on an ABI PRISM
7900 HT sequence detection system (Applied Biosys-
tems). The pre-run thermal cycling conditions were 10
minutes at 95°C to activate the Taq DNA polymerase,
followed by 40 cycles of 95°C for 15 seconds and 60°C
annealing/extension for 1 minute. Each experiment was
performed in triplicate. Within each experiment, reactions
were run in triplicate. Relative gene expression levels
were determined by the comparative threshold cycle
method (CT).
34 For statistical analysis of the expres-
sion data, the independent samples t-test was used.
Results
Kidney Histology and Ultrastructure
H&E-stained kidney specimens of untreated GneM712T/M712T
mice and their wild-type littermates were examined at E19
or at P2, because mutant pups die before P3.29 At E19,
there were no apparent histological differences between
wild-type and mutant mice (see Supplemental Figure S2A
at http://ajp.amjpathol.org). This was confirmed at the ul-
trastructural level, with embryonic glomeruli of mutant
mice resembling those of control littermates. Embryonic
glomeruli have predominantly cuboidal podocytes (epi-
thelial cells) with occluding junctions. In most podocytes,
foot processes have not yet appeared; the basement
membrane is slender and immature, and endothelial cells
show only sporadic fenestrae (Figure 1A).35,36
Figure 1. Ultrastructural analyses of juxtamed-
ullary glomeruli in mouse kidneys. Representa-
tive electron microscopy images of juxtamedul-
lary glomeruli in kidney sections of control
(/ or /) and mutant GneM712T/M712T
(/) littermate pups. A: At embryonic day 19
(E19), no ultrastructural differences in the glo-
merular filtration apparatus were observed be-
tween control and mutant littermate pups. No
endothelial (en) fenestrae have yet formed, and
the GBM (asterisk) remains immature. Most
podocytes (pd) showed effaced foot processes
with occluding junctions (arrows). Scale bars:
500 nm. B: At postnatal day 2 (P2), control glom-
eruli contain interdigitating foot processes with
open filtration slits, an intact GBM and fenes-
trated endothelial cells (en). In contrast, mutant
glomeruli revealed podocyte (pd) foot process
effacement with very few filtration slits, segmen-
tal splitting of the GBM (asterisk), and seem-
ingly normally fenestrated endothelium (en).
Scale bars: 1 m. C: In ManNAc-supplemented
mutant pups at P10 (P10ManNAc) the podo-
cyte effacement is partially restored with intact
filtration slits between foot processes. The litter-
mate control glomeruli showed normal separa-
tion of foot processes with patent endothelial
fenestrae and an intact GBM. Scale bars: 1 m.
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showed surface petechial hemorrhages.29 Histologically,
mutant kidneys exhibited increased amounts of embry-
onic metanephric mesenchyme, compared with wild-type
kidneys (see Supplemental Figure S2B at http://ajp.
amjpathol.org). Glomeruli were remarkable for mesangial
expansion (see Supplemental Figure S3 at http://ajp.
amjpathol.org). Focally, tubules were remarkable for noni-
sometric vacuolization, red blood cell casts, dilation, and
atrophic epithelium. Ultrastructurally, podocyte efface-
ment and segmental splitting of the GBM was apparent in
mutant kidneys at P2 (Figure 1B), as described previ-
ously.29 These severe ultrastructural changes likely ac-
count for both the hematuria and proteinuria and the early
lethal phenotype.
In GneM712T/M712T mice that were treated with Man-
NAc, kidneys at P5 demonstrated substantial amounts of
uninduced mesenchyme, compared with ManNAc-
treated wild-type littermates (see Supplemental Figure
S2B at http://ajp.amjpathol.org). In addition, ManNAc-
treated mutant pups still manifested increased matrix
staining of glomeruli (see Supplemental Figure S2C at
http://ajp.amjpathol.org). Focal tubular vacuolization, red
blood cell casts, and proteinaceous casts persisted in
mutant ManNAc-treated mice, although to a lesser extent
than in untreated mice at P2. Ultrastructurally, however,
glomeruli of ManNAc-treated GneM712T/M712T mice showed
a dramatic improvement, with increased foot process for-
mation and reduced GBM splitting (Figure 1C). These
changes were likely responsible for survival of mutant
mice beyond P3.29
Urine Gel Electrophoresis
Proteinuria of GneM712T/M712T mice was further examined
using urinary gel electrophoresis. It appeared that the
major urinary proteins of GneM712T/M712T mice were albu-
min and a few other higher molecular weight proteins
(Figure 2; see also Supplemental Figure S4A at http://ajp.
amjpathol.org). Semiquantitative determination of albumin
concentrations showed albuminuria of approximately
0.30 g/L in untreated mutant mice (at P2), which was
reduced by approximately 25% (to 0.22 g/L) after
ManNAc treatment at P5, indicating improved glomerular
filtration after treatment (Figure 2; see also Supplemental
Figure S4B at http://ajp.amjpathol.org).
Figure 2. Urine gel electrophoresis. Mouse urine samples (2 L) were
electrophoresed on a 4% to 20% Tris-glycine polyacrylamide gel and stained
with Coomassie Brilliant Blue. The major protein band on the gel was
albumin (66.7 kDa); for the entire gel image, see Supplemental Figure S4A
(available at http://ajp.amjpathol.org). Densitometry quantifications of albu-
min concentrations in each sample are given below the gel image (see also
Supplemental Figure S4B at http://ajp.amjpathol.org).Lectin Staining Panel
We used a panel of lectins (ie, sugar-binding proteins
with ligand specificities for defined carbohydrate se-
quences37) to examine the sialylation status of the glo-
merular glycocalyx on paraffin-embedded kidney
slides from wild-type and mutant GneM712T/M712T
mice before and after ManNAc treatment. We used
six lectins: WGA, SNA, PNA, Jacalin, HPA, and VVA
(Figure 3).
WGA (wheat germ agglutinin from Triticum vulgaris)
predominantly recognizes terminal sialic acid (Neu5Ac)
and N-acetylglucosamine (GlcNAc) on glycans.37–39
SNA (elderberry bark agglutinin from Sambucus nigra)
predominantly recognizes terminal sialic acid (Neu5Ac)
in an (2,6)-linkage with either galactose (prevalent in
N-linked glycans) or with N-acetylgalactosamine
(GalNAc) (found in O-linked glycans).38,40 WGA and
SNA signals were localized primarily to the glomerular
epithelial podocytes in E19, P2, and P5 kidneys. Wild-
type glomeruli exhibited similar WGA and SNA staining
intensities across all ages; mutant glomeruli showed de-
creased WGA and SNA staining at E19 and P2, com-
pared with the wild type, with recovery of the signals at P5
after ManNAc treatment.
PNA (peanut agglutinin from Arachis hypogaea) prefer-
entially binds to terminal galactose (Gal) linked to
GalNAc residues [Gal-(1,3)-GalNAc],37,38,41 and there-
fore outlines predominantly hyposialylated O-linked gly-
cans. PNA did not significantly stain wild-type sections,
indicating that O-linked glycoconjugates are mostly
sialylated, as expected. However, mutant kidneys at
E19 and at P2 showed significant PNA signal, outlining
mainly the podocytes of the glomerular epithelium and
indicating the presence of hyposialylated glycans. In
ManNAc-supplemented mutant pups at P5, the PNA sig-
nal appeared reduced, reflecting partial glomerular re-
sialylation and/or dilution of the PNA signal consequent to
increased membrane surface due to recovery of podo-
cyte foot process formation (Figure 3C).
Jacalin (jackfruit agglutinin from Artocarpus integrifolia),
like PNA, binds to terminal Gal-(1,3) -GalNAc residues,
but can also recognize sialylated O-linked glycans (sialic
acid-Gal-GalNAc).42,43 Jacalin and PNA staining pat-
terns appeared similar for the embryonic and P2 speci-
mens (ie, increased staining in mutant glomeruli, com-
pared with the wild type). In ManNAc-treated mutant
glomeruli, the PNA signal appeared more attenuated
than the Jacalin signal (Figure 3C).
HPA (edible snail agglutinin from helix pomatia) and
VVA (hairy vetch agglutinin from Vicia villosa) predomi-
nantly bind GalNAc O-linked to serine or threonine resi-
dues of proteins.38,44–46 Staining with HPA was absent
from all wild-type glomeruli, as expected, but mutant
kidneys at all ages showed a glomerular epithelial stain-
ing pattern similar to that of PNA and Jacalin. The HPA
and VVA signals were greatly diminished after ManNAc
treatment.
The lectin staining panel established the onset of hy-
posialylation in mutant glomeruli at the embryonic stage
(Figure 3A). Compared with staining of mutant glomeruli
i retain r
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nals was greatly reduced at P2 (Figure 3B). This change
may be attributed to the larger surface area of the grow-
ing and interdigitating epithelial cells at P2, compared
with E19, or may reflect a partial increase of O-linked
sialylation after birth in mutant glomeruli. ManNAc sup-
plementation appeared to attenuate sialylation status in
mutant glomeruli at P5 (Figure 3C).
Immunoblotting of Podocalyxin and Nephrin
Immunoblotting of kidney extracts showed hyposialyla-
Figure 3. Lectin histochemistry of kidney juxtamedullary glomeruli. Repres
FITC-labeled lectins WGA, SNA, PNA, Jacalin, HPA, and VVA (green) and th
all ages and genotypes per lectin. A: Embryonic kidneys at E19 showed decre
wild-type (/) littermate glomeruli. PNA, Jacalin, HPA, and VVA bind only
in these glomeruli. B: Kidneys from pups at P2 showed decreased WGA an
glomeruli bind PNA, Jacalin, HPA, and VVA, indicating hyposialylation of O
glomeruli, which could be attributed to increased membrane surface at P2 (d
after birth. C: Kidneys from ManNAc-treated pups at P5 showed more inte
suggestive of increased sialylation. After ManNAc treatment, mutant glomerul
did not fully restore sialylation.tion of the glomerular sialoprotein podocalyxin, as evi-denced by an upward shifted protein band due to re-
duced negative charge, not only in mutant pups at P2, as
previously reported,29 but also in embryonic mutant kid-
neys (Figure 4A).
Immunoblotting for the glomerular glycoprotein neph-
rin demonstrated hyposialylation of nephrin in kidney ex-
tracts of mutant mice at P2, as evidenced by a lower
molecular weight band similar in size to that of kidney
extracts of wild-type and heterozygous mice at P2 that
were desialylated by neuraminidase treatment (Figure
4B). After ManNAc treatment at P5, the molecular weight
and sialylation of nephrin in mutant kidneys was restored
images of mature juxtamedullary glomeruli in mouse kidneys stained with
uclear dye (blue). Confocal imaging intensity settings were the same across
A and SNA staining patterns and intensity for mutant (/), compared with
ant glomeruli, indicating hyposialylation of predominantly O-linked glycans
taining intensity in mutant glomeruli, compared with the wild type. Mutant
lycans. The staining intensity at P2 is decreased, compared with embryonic
f the glycan signals) and/or partial amelioration of the hyposialylation status
als in mutant glomeruli for WGA and SNA, compared with the wild type,
esidual staining for PNA, Jacalin, HPA, and VVA, indicating that the treatmententative
e DAPI n
ased WG
to mut
d SNA s
-linked g
ilution o
nse signto that of wild-type kidneys (Figure 4B).
/) at P
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Various hereditary forms of proteinuria and/or hematuria
can be attributed to defects in genes coding for structural
proteins of the glomerular filtration apparatus; most such
disorders involve GBM splitting and/or podocyte efface-
ment.47 Some unexplained forms of congenital protein-
uria and hematuria have recently been attributed to novel
genetic mechanisms, such as defects in signaling path-
ways48,49 or micro-RNAs.50,51 However, few studies have
addressed the consequences of glomerular glycocalyx
defects. The glomerular glycocalyx is enriched in glyco-
conjugates, including proteoglycans, glycosaminogly-
cans, and sialoglycoproteins; it contributes to the size-
and charge-selectivity of the glomerular filtration barrier.
All three components of the filtration barrier (fenestrated
endothelial cells,52 GBM53,54 and epithelial podocytes55)
contain a glycocalyx.
Sialic acids, which are terminal, negatively charged
residues on most glycoconjugates, play crucial roles in
formation, maintenance, and function of the glomerular
glycocalyx. Experimental evidence indicated that re-
moval of glomerular sialic acids by infusion of sialidase,5
or charge neutralization of sialic acids by polyca-
tions,18,56 resulted in foot process effacement and pro-
teinuria. In addition, experimental desialylation of podo-
calyxin, the major glomerular sialoglycoprotein, resulted
in foot process effacement and proteinuria.16
In the present study, we further characterized the
unique glomerulopathy of our previously described
GneM712T/M712T mouse model, which appeared lethal be-
tween birth and P3.29 We now have established that the
glomerulopathic process begins in the embryonic stage,
because lectin staining demonstrated hyposialylation
(Figure 3) and immunoblotting showed hyposialylation of
podocalyxin (Figure 4) in GneM712T/M712T embryonic kid-
neys. This occurred even though no histological or ultra-
structural abnormalities were identified in GneM712T/M712T
embryonic kidneys, compared with wild-type littermates
(Figure 1A; see also Supplemental Figure S2A at http://
ajp.amjpathol.org). We surmise that hyposialylation per-
mits some maturation of the glomerular filtration appara-
tus in utero, allowing GneM712T/M712T mice to survive the
Figure 4. Immunoblotting of podocalyxin and nephrin. A: Immunoblot of k
to 150 kDa) and -tubulin (55 kDa, loading control). Wild-type (/) (la
Slower hyposialylated podocalyxin migration (160 to 180 kDa) in GneM712T/
B: Immunoblots of kidney extracts labeled with antibodies against nephrin (
ladder. Wild-type (/) (lanes 2 and 3) and heterozygous Gne/M712T (/
neuraminidase, resulting in nephrin migrating faster than untreated sample
running desialylated nephrin signal, which did not change after neuramini
Gne/M712T (/) (lane 2), and mutant (/) (lanes 3 and 4) kidney extra
Nephrin recovered after ManNAc treatment in kidney extracts of mutants (
(/) (lane 5) kidney extracts at P5.embryonic stage, in contrast to complete Gne knockoutmice that were embryonic lethal.28 Nevertheless, at P2,
GneM712T/M712T kidneys showed a delayed maturation of
glomeruli and a failure to form podocyte foot processes.
Administration of the sialic acid precursor ManNAc to
GneM172T/M712T mice partially rescued this phenotype
and allowed for the survival of mutant pups beyond P3.29
We previously reported increased urinary protein (500
mg/dL, measured by dipstick) in mutant GneM712T/M712T
mice.29 In the present study, we characterized the pro-
teinuria by gel electrophoresis of mouse urine. The major
urinary proteins of GneM712T/M712T mice were albumin
and a few other higher molecular weight proteins (Figure
2; see also Supplemental Figure S4 at http://ajp.
amjpathol.org). These findings indicate glomerular injury
rather than tubular defects in GneM712T/M712T mice.57
Semiquantitative determination of albumin concentra-
tions showed albuminuria of approximately 0.30 g/L in
untreated mutant mice (at P2), which was reduced by
approximately 25% (to0.22 g/L) after ManNAc treat-
ment in GneM712T/M712T mice at P5, indicating improved
(but still affected) glomerular filtration after treatment.
Note that untreated wild-type and heterozygous mice at
P2 also have minor albuminuria (0.06 g/L), likely due
to immature glomerular development at this age, which
was not present in urine of wild-type mice at P5.
The initiation signals for development of podocyte foot
processes and formation of slit diaphragms are largely
unknown. Increased blood pressure58 and the insertion of
podocalyxin in the apical portion of the podocyte mem-
brane11,59 have been suggested as triggers. In fact, we
documented hyposialylated podocalyxin in GneM172T/M712T
kidneys, and ManNAc supplementation restored podo-
calyxin sialylation as well as podocyte foot process and
slit diaphragm formation. Of note, podocalyxin knockout
mice, in contrast to our GneM712T/M712T mice, do not have
abnormalities of the GBM.11 This suggests that reduced
sialylation of other sialoproteins may account for the GBM
splitting seen in our mice. Podocytes are linked to the
GBM through a number of sialylated anchoring mole-
cules, such as 13 integrin and /-dystroglycans.60–62
These molecules facilitate crosstalk between the GBM
and the podocytes and determine podocyte structure
tracts (ages P2 and E19) labeled with antibodies against podocalyxin (140
nd 5) and heterozygote (/) (lane 2) specimens show normal migration.
/) is present in utero (E19; lane 4) and continues postnatally (P2, lane 3).
a) and -tubulin (55 kDa, loading control). Left: Lane 1: Molecular weight
s 4 and 5) kidney extracts were left untreated or treated for desialylation by
t GneM712T/M712T (/) (lanes 6 and 7) kidney extracts showed the faster
atment in mutant kidneys. Right: Wild-type (/) (lane 1), heterozygous
2 demonstrate hyposialylation of nephrin in mutant (/) kidney extracts.
5 (P5ManNAc) (lanes 6 and 7); also shown are ManNAc-treated wild-typeidney ex
nes 1 a
M712T (
180 kD
) (lane
s. Mutan
dase tre
cts at Pand possibly also the composition of the GBM. Altered
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may account for the observed GBM changes, through
altered signaling and dysregulation of GBM synthesis.
Other sialoproteins may also play a role in the glomer-
ular pathology of our mouse model. We previously tested
a series of glomerular proteins by immunoblotting for
sialylation status in GneM172T/M712T kidneys [including
laminin-1, podocin, laminin 1, desmin, and VSMA (-
SMA)], but did not find any abnormal intensity or size
difference, compared with wild-type kidneys.29 Some
other candidate proteins may arise from mouse models
with defects in genes encoding proteins residing in podo-
cytes or slit diaphragms (eg, angiopoietin-like 4 pro-
tein,63 integrin 1,61 Neph1,64 or CD2AP55); these model
mice exhibit effaced podocytes leading to nephrosis and
death hours to weeks after birth. Whether these proteins
are sialylated and affected in our mice remains unknown.
Because nephrin-deficient mice65 and human nephrin-
deficiency [resulting in congenital nephrotic syndrome of
the Finnish type (NPHS1; OMIM 256300)]47,66 showed a
similar renal phenotype as our GneM172T/M712T mice, we
investigated nephrin sialylation in kidney extracts of our
mice. Surprisingly, immunoblotting demonstrated hypo-
sialylated nephrin in GneM172T/M712T mice (Figure 4B),
consistent with in vitro studies of nephrin deglycosyla-
tion.67 Kidney extracts from ManNAc-treated mutant
mice at P5 showed recovery of nephrin sialylation after
treatment. Nephrin is a transmembrane glycoprotein ex-
pressed by podocytes and is a structural component of
the glomerular slit diaphragm. Nephrin molecules from
adjacent foot processes are thought to interact in the
middle of the slit to form a filtering structure.68 Nine of 10
potential N-linked glycosylation sites in nephrin were ex-
perimentally proven to be modified by N-linked glycosy-
lation.67 O-linked nephrin glycosylation has not been
experimentally examined, but database searches pre-
dict five potential O-glycosylation sites (NetOGlyc 3.1
server; http://www.cbs.dtu.dk/services/NetOGlyc). Future
research may reveal which glycan structures on nephrin
are hyposialylated in our GneM172T/M712T mice. N-linked
glycosylation on nephrin was shown to be critical for
folding and localization of the protein, and thus has been
suggested to be an important factor in the pathogenesis
of glomerular diseases.69
Rather than investigating each podocyte and slit dia-
phragm-associated candidate protein individually, we
used a lectin panel to determine overall glomerular gly-
cosylation status in our mice. We demonstrated hyposia-
lylation of predominantly O-linked glycans in the glomer-
ular glycocalyx of GneM712T/M712T mice by showing
increased binding of the lectins PNA, Jacalin, HPA, and
VVA to GneM712T/M712T glomeruli. Although ManNAc
treatment did not appear to completely restore the overall
hyposialylation pattern, it is likely that sialylation of
certain sialoproteins is restored on ManNAc supple-
mentation, as was demonstrated for podocalyxin and
nephrin by immunoblotting (Figure 4). It is possible that
sialyltransferases have different affinities for CMP-
sialic acid70–72 and that, with a paucity of sialic acid,
certain glycans may be preferentially sialylated. Sialyl-
transferase expression itself may also be regulated bysialic acid availability and/or the amount of Gne
mRNA.73 However, we encountered normal Gne mRNA
expression levels in GneM712T/M712T mice.29
Increased neuraminidase expression and activity was
previously suggested to play a role in glomerular hypo-
sialylation of certain renal diseases.60,74 We therefore
determined mRNA expression of lysosomal (Neu1) and
cytoplasmic (Neu2) neuraminidase in our mouse kidneys
(see Supplemental Figure S5 at http://ajp.amjpathol.org).
We found a significant decrease of both Neu1 and Neu2
expression in mutant kidneys, compared with wild-type
kidneys at P2, perhaps indicating a possible down-reg-
ulation of neuraminidase expression in response to glo-
merular hyposialylation in mutant kidneys at P2 due to the
Gne defect. After ManNAc treatment, mutant and wild-
type kidneys showed similar Neu1 and Neu2 expression
rates, consistent with recovery of sialylation status in mu-
tant mice. Note the high expression of Neu1 and Neu2
mRNA in wild-type kidneys at P2, compared with P5,
which may be related to the high demand for sialic acid
in the first few days after birth.75
In humans, hyposialylation has been suggested in sev-
eral unexplained glomerulopathies, including minimal
change nephrosis,7,8 membranous glomerulonephritis8
and IgA nephropathy.9,10 Other disorders involving pro-
teinuria and/or hematuria for which the etiology is un-
known may also be related to changes in glomerular
sialylation. These include certain forms of focal and seg-
mental glomerulosclerosis,76 membranous glomerulone-
phritis,77 lupus nephritis,78, and other idiopathic nephritic
syndromes.79 Our lectin staining panel can be applied as
a simple diagnostic tool to identify human renal disorders
of hyposialylation. Moreover, if the human hyposialylation
pattern proves to be similar to that in our mouse model,
ManNAc might be explored as a therapeutic option.6,80
One must keep in mind, however, that untreated
GneM712T/M712T mice had a severe congenital glomerular
phenotype and did not survive the postnatal days, unless
treated throughout the embryonic stage with ManNAc,
and humans likely would also not survive the postnatal
period with such a severe phenotype. Nevertheless, hu-
man glomerulopathies with hyposialylation, whether con-
genital or acquired later in life, remain good candidates
for ManNAc therapy.
The use of ManNAc for the treatment of HIBM patients
is being pursued. Other suggested therapies to increase
sialylation involve intravenous immunoglobulins as a
source of sialic acid31 or administration of acute phase
reactants (-1-acid glycoprotein or orosomucoid), which
improved nephritic syndrome in rats.81,82 Testing various
drug delivery mechanisms for efficient delivery to kidney
glomeruli will be useful for future therapeutic develop-
ment. Caution is required, with attention paid to the dif-
ference between humans and other mammals used to
test therapies, because most mammalian species use the
sialic acid Neu5Gc (N-glycolylneuraminic acid), but hu-
mans have lost the ability to synthesize Neu5Gc and rely
on Neu5Ac as their main sialic acid.32 In addition,
protein glycosylation patterns vary among tissues
and/or species; in particular, the contingent of O- and
Hyposialylation in Glomerulopathy 1439
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widely among species.33
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